CML Statistics

Based on CML statistics, the American Cancer Society has estimated that 4,500 American men and women will be diagnosed with chronic myeloid leukemia in 2006. Other statistics concerning CML indicate that during 1998-2002, the median age at diagnosis for chronic myeloid leukemia was 66 years of age. CML statistics show that the overall five-year relative survival rate for the disease during 1995-2001 was 39 percent.

CML Statistics: 2006 Estimates

The American Cancer Society estimated that 4,500 men and women (2,550 men and 1,950 women) would be diagnosed with chronic myeloid leukemia (CML) in 2006. Chronic myeloid leukemia is also known as chronic myelogenous leukemia and chronic granulocytic leukemia.
 

CML Statistics: Incidence

During 1998-2002, the median age at diagnosis for chronic myeloid leukemia was 66 years of age. The percentages of people diagnosed with CML based on age were:
 
  • 2.4 percent were diagnosed under age 20
  • 8.6 percent between 20 and 34
  • 10.3 percent between 35 and 44
  • 12.4 percent between 45 and 54
  • 13.4 percent between 55 and 64
  • 19.5 percent between 65 and 74
  • 23.6 percent between 75 and 84
  • 9.7 percent 85+ years of age.
 
The age-adjusted incidence rate for CML was 1.6 per 100,000 men and women per year. Incidence rates by race and sex were:
 
Race/Ethnicity
Men
Women
All Races
2.1 per 100,000 men
1.2 per 100,000 women
Caucasian
2.1 per 100,000 men
1.3 per 100,000 women
African American
1.9 per 100,000 men
1.0 per 100,000 women
Asian/Pacific Islander
1.6 per 100,000 men
0.9 per 100,000 women
Hispanic
1.7 per 100,000 men
1.0 per 100,000 women
 
Do You Recognize These 13 Celebrity E-Cigarette Smokers?

CML

Referring Pages:
Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2017 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.